Israel’s First Pure-Play Cannabis Company
This Isracann Biosciences Inc. profile is part of a paid investor education campaign.*
Isracann Biosciences Inc. (CSE:IPOT) is an Israeli-based cannabis company focused on becoming a premier low-cost cannabis producer. To this aim, the company is developing its fully-funded 230,000-square-foot cultivation facility near Tel Aviv, Israel. Isracann plans to target the undersupplied domestic and European markets with high-quality medical cannabis products manufactured at its facility.
The facility is being built to ISL and EU-GMP standards, and the company is applying for IMC-GAP and GSP certification, which allows Isracann to export its products and brands into Europe. The building is also designed to be a hybrid greenhouse, allowing the company to capitalize on Israel’s ideal climate and growing conditions.
Israel is high in humidity and has ideal year-round temperatures, which allow cannabis companies to reduce production costs significantly. The country receives, on average, 300 days of sun per year and high UV rays, which contributes to higher crop yields, more growing cycles and helps lower production costs. These factors help Isracann keep its production rates as low as C$0.40 per gram.
Once the building is complete, Isracann expects to produce up to 23,500 kilograms annually.
Isracann’s Company Highlights
- Isracann is focused on becoming a premier low-cost cannabis producer in Israel and the EU.
- The European cannabis market is expected to be worth 123 billion euros by 2028.
- Isracann is developing a fully-funded 230,000-square-foot cultivation facility near Tel Aviv.
- Once complete, the facility can produce up to 23,500 kilograms of cannabis annually.
- The facility is being built to EU-GMP standards, a necessity for exporting cannabis to the EU.
- Isracann is also pursuing IMC-GAP and GSP certification for the facility to ensure that the company can export its products.
- Israel offers an optimal environment to grow cannabis as it is high in humidity, has ideal temperatures and receives, on average, 300 days of sunshine.
- The hybrid nature of Isracann’s cultivation facility allows the company to effectively utilize Israel’s climate, reducing production costs and increasing yields.
- Isracann is targeting low-cost production at its facility at only C$0.40 per gram.
The Israel Opportunity
Israel has been a pioneer in cannabis R&D for decades, making use of its global leadership in agricultural technology. In the early 1990s, a medical cannabis program was implemented to help cancer patients with pain-related issues. Today, Israel has approximately 46,000 registered medical cannabis patients. After initiating a new medical cannabis regime in April 2019, the country has been experiencing cannabis shortages, leaving many patients without access to their medicine.
Cannabis companies are now looking to secure a first-mover advantage in the country to fulfill the demand for medical cannabis. Israel offers cannabis cultivators an optimal environment to grow cannabis. The country is high in humidity, which acts as a natural bug deterrent, and has ideal year-round temperatures, which allow cannabis companies to reduce production costs significantly. The country receives, on average, 300 days of sun per year and high UV rays, which contributes to higher crop yields, more growing cycles and helps lower production costs.
In January 2019, Israel approved a framework that allows exports of medical cannabis which is expected to be announced as law and live in Q2 2020. Cannabis companies are required to be approved by the health regulators and police before exporting any product. Being able to export medical cannabis out of the country allows cannabis companies to move into the European cannabis market.
Europe is home to over 740 million people and is set to become one of the largest cannabis markets in the world. According to a report by Prohibition Partners, the European cannabis market is expected to be worth 123 billion euros by 2028. Growth of the market is attributed to the number of pro-cannabis legislative changes being passed or considered in numerous countries across the continent.
Isracann is developing a fully-funded 230,000-square-foot cultivation facility near Tel Aviv, Israel, designed to meet ISL and EU-GMP manufacturing practices. The company is in the process of gaining its IMC-GAP and GSP certification, allowing Isracann to export its products and brands into Europe as regulations allow.
Israel’s climate is ideal for cannabis cultivation. Isracann is deploying modern greenhouse canopies at its facility to ensure that the company has the highest quality production environment at the lowest potential cost. The building’s 12 canopy layout is modular in design, making it cost-effective, scalable and easily accessible for irrigation, electrical distribution and maintenance.
Once complete, the facility is expected to have an annual capacity of 23,500 kilograms. The company plans to distribute its products to medical cannabis users within Israel as well as to the EU as regulations allow.
Isracann’s Management Team
Daryl Jones — President and CEO
Daryl Jones has over 15 years of capital market experience and an established financial network. Prior to joining Isracann in 2018, he was an Investment advisor with PI Financial Corp. Canada and Raymond James Ltd. Canada. He was responsible for raising significant risk capital for growth companies in all sectors, with a particular focus on medical cannabis and natural resources. Jones took True Leaf Medicine public in early 2014 at $10 million valuation and exited in 2016 at $150 million market capitalization.
Irit Arbel, Ph.D. – Director
Dr. Irit Arbel served as Director and President of Brainstorm Cell Therapeutics, Executive VP of R&D at Savicell Diagnostic and previously as Chairperson of Real Aesthetics (cellulite ultrasound) and BRH Medical (wound healing). Previously, Director of M&A at RFB Investment House (early stage technology-related focus). President and Chief Executive Officer of Pluristem Life Systems, and Israeli Sales Manager of Merck, Sharp & Dohme pharmaceutical. Earned her PhD in 1997 in Neurobiology, and holds a Chemical Engineering degree from the echnion, Israel’s Institute of echnology
This profile is sponsored by Isracann Biosciences Inc. (CSE:IPOT). This profile provides information which was sourced by the Investing News Network (INN) and approved by Isracann Biosciences Inc., in order to help investors learn more about the company. Isracann Biosciences Inc. is a client of INN. The company’s campaign fees pay for INN to create and update this profile.
INN does not provide investment advice and the information on this profile should not be considered a recommendation to buy or sell any security. INN does not endorse or recommend the business, products, services or securities of any company profiled.
The information contained here is for information purposes only and is not to be construed as an offer or solicitation for the sale or purchase of securities. Readers should conduct their own research for all information publicly available concerning the company. Prior to making any investment decision, it is recommended that readers consult directly with Isracann Biosciences Inc. and seek advice from a qualified investment advisor.